Format

Send to

Choose Destination
Clin Lab Med. 2016 Sep;36(3):473-91. doi: 10.1016/j.cll.2016.05.010. Epub 2016 Jun 24.

Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins.

Author information

1
Genomas Inc., 67 Jefferson Street, Hartford, CT 06106, USA. Electronic address: g.ruano@genomas.net.
2
Sanofi Genzyme, 500 Kendall Street, Cambridge, MA 02142, USA.
3
Cyclica Inc., 10 Jonathan Street, Belmont, MA 02478, USA.
4
Department of Laboratory Medicine, San Francisco General Hosptial, 1001 Potrero Avenue, San Francisco, CA 94110, USA.
5
Division of Cardiology, Hartford Hospital, 80 Seymour Street, Hartford, CT 06106, USA.

Abstract

Statin responsiveness is an area of great research interest given the success of the drug class in the treatment of hypercholesterolemia and in primary and secondary prevention of cardiovascular disease. Interrogation of the patient's genome for gene variants will eventually guide anti-hyperlipidemic intervention. In this review, we discuss methodological approaches to discover genetic markers predictive of class-wide and drug-specific statin efficacy and safety. Notable pharmacogenetic findings are summarized from hypothesis-free genome wide and hypothesis-led candidate gene association studies. Physiogenomic models and clinical decision support systems will be required for DNA-guided statin therapy to reach practical use in medicine.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00767130.

KEYWORDS:

Coenzyme Q(10); Lipid metabolism; Myalgia; Myopathy; PCSK9 inhibitors; Pharmacogenetics; Physiogenomics; Statins

PMID:
27514463
PMCID:
PMC4987540
DOI:
10.1016/j.cll.2016.05.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center